about
Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse.[Therapeutic potential of melatonin in cancer treatment]Is it important to adapt neoadjuvant chemotherapy to the visible clinical response? An open randomized phase II study comparing response-guided and standard treatments in HER2-negative operable breast cancerBCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosisComparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer.Temozolomide and unusual indications: review of literature.Neurotoxicity as a prognostic factor in patients with metastatic breast cancer treated with ixabepilone as a first-line therapy.Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer.Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.Dietary methionine restriction with FOLFOX regimen as first line therapy of metastatic colorectal cancer: a feasibility study.TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer.Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin.Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.[Stress, cancer and circadian rhythm of melatonin]Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impactMammalian target of rapamycin inhibitors in combination with letrozole in breast cancerChanges in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapySentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentationA new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN)Neoadjuvant endocrine therapy in breast cancerMeasurement of residual disease after neoadjuvant chemotherapyPrognostic value of initial tumor parameters after metastatic relapseIntraoperative imprint cytology examination of sentinel lymph nodes after neoadjuvant chemotherapy in breast cancer patientsMetastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line?Clinicopathological factors and nomograms predicting nonsentinel lymph node metastases after neoadjuvant chemotherapy in breast cancer patientsLate lines of treatment benefit survival in metastatic breast cancer in current practice?Does regional lymph node irradiation improve the outcome of N0 and pN0 breast cancer?The role of tomosynthesis in breast cancer staging in 75 patientsTreatment-Induced Cardiotoxicity in Breast Cancer: A Review of the Interest of Practicing a Physical ActivityWeight Evolution During Endocrine Therapy for Breast Cancer in Postmenopausal Patients: Effect of Initial Fat Mass Percentage and Previous Adjuvant TreatmentsImpact of Chemotherapy-induced Menopause in Women of Childbearing Age With Non-metastatic Breast Cancer - Preliminary Results From the MENOCOR Study
P50
Q30992559-FA15A95C-FB94-40C1-BE60-284D66A4597CQ33366654-EE771AE7-1F9A-4A95-BD1F-9E72EE8BB441Q35151131-6E10DFCD-606A-4143-87E3-D6DE0D61CA50Q35909731-61B577CC-8CF4-4E52-A493-58D10F537246Q36175526-F8E56B41-8D01-4777-8B84-755788FE9565Q37189169-BC07CA9B-F063-4805-B78E-54FDDCB5C8E3Q38028028-1ED3E8D0-85DA-46E3-8BF0-BAD1659A1BB2Q38282705-6DC3D83B-C94A-48BC-A4BE-FA85F8D26440Q38432663-E592F940-4C51-457D-8B69-2DC8515A204AQ38434805-D75499CF-FED5-47E2-B340-1F8BA3866472Q40103479-7A316788-B6A3-40E4-B31F-73301C2ED2A8Q41233301-9656300D-44FC-46B7-AD5F-6BBDC6EA919AQ43083534-5E9334B6-637E-4F0A-A2B9-7B6BBDFD9C88Q44378342-BA8460F9-73B3-4643-B9AE-71928460A901Q45126382-ACC38D99-1743-430F-B55B-BAF9F0769E01Q46192906-BAD61704-0761-493D-AEA6-1FB2B13A49D5Q46530693-0631A48F-A983-4CCB-8BF2-619F9DCFEC2DQ53648917-4CA0DCEE-FD77-4128-BD7B-7E20A6E61649Q53805931-107B04F7-1ACB-4C1E-8066-3FDBF4877BACQ57579477-836882C4-558E-4068-8F95-E60C83ACF3B5Q79339657-F0A6533E-377C-40C6-8253-54715BF7238AQ80548300-A677FC1E-3315-43F0-834E-7F4BE3918DE0Q80800181-3CBF14E6-89A7-44F0-BE97-A4170E3A5285Q81025246-DC17774C-A3D7-437B-A9C4-E30329D3C533Q81361849-32C87A73-2DE2-469C-A5FC-F687821EEB77Q81484644-355C584D-E7A0-4A67-B0A9-DB1AFDE32402Q82096460-93E6705C-2DAE-4A45-B4B4-08BCD12640F1Q82898371-C9632BE0-876D-4400-873E-9AACB367CD35Q83291101-CADE844B-E2F3-405F-B9DA-A7A465D3D16DQ83756422-CEB80C37-2324-44A0-BEC6-ECFA31FE74A8Q84789353-85F3F0E8-4F02-4521-94E3-C1BEEEF367B0Q84996963-36FEE883-D953-43A7-B8CA-77CBD3E46D2BQ87491233-D04333DB-6636-4C82-8D31-B3683626D3A6Q92823241-B4E454F2-95FD-49F3-8182-E79126BB5A30Q92998115-6C9F82C2-39B6-4422-92C9-48D36042B873Q93192218-18A05B5C-C47B-4D08-A89B-D92D4F5937F9
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Catherine Abrial
@en
Catherine Abrial
@nl
type
label
Catherine Abrial
@en
Catherine Abrial
@nl
prefLabel
Catherine Abrial
@en
Catherine Abrial
@nl
P31
P496
0000-0002-1759-9457